Neurons and mechanisms of neuronal death in neurodegenerative diseases: A brief review

Laboratory Animal Science

Volumn 49, Issue 4, 1999, Pages 358-362

  Waggie, Kimberly S ^a   Kahle, Philipp J ^b   Tolwani, Ravi J ^c  

^a ZYMOGENETICS INC   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL LOSS; DEGENERATIVE DISEASE; HUMAN; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; REVIEW;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 0032828984     PISSN: 00236764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Jubb, K. V. F., and C. R. Huxtable. 1993. The nervous system, p. 292-309. In K. V. F. Jubb, P. C. Kennedy, and N. Palmer (ed.), Pathology of domestic animals. Academic Press, Inc., San Diego, Calif.
2. Koestner, A., and T. C. Jones. 1997. The nervous system, p. 1259-1264. In T. C. Jones, R. D. Hunt, and N. W. King (ed.), Veterinary pathology. Williams and Wilkins, Baltimore.
3. DeGirolami, U., M. P. Frosch, and D. C. Anthony. 1994. The central nervous system, p. 1296-1298. In R. S. Cotran, V. Kumar, and S. L. Robbins (ed.), Robbins pathologic basis of disease. W. B. Saunders Co., Philadelphia.
4. Cross, P. C., and K. L. Mercer. 1993. Nerve, p. 124-145. In Cell and tissue ultrastructure: functional perspective. W. H. Freeman & Co., New York.
5. Hoffman, B. B., R. J. Lefkowitz, and P. Taylor. 1996. Neurotransmission: the autonomic and somatic motor nervous systems, p. 105-139. In J. G. Hardman and L. E. Limbird (ed.), Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill Book Co., New York.
6. Bloom, F. E. 1996. Neurotransmission and the central nervous system, p. 267-293. In J. G. Hardman and L. E. Limbird (ed.), Goodman's and Gilman's the pharmacological basis of therapeutics. McGraw-Hill Book Co., New York.
7. Kerr, J. F., A. H. Wyllie, and A. R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-257.
8. Majno, G., and I. Joris. 1995. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 146:3-15.
9. Raff, M. C., B. A. Barres, J. F. Burne, et al. 1993. Programmed cell death and the control of cell survival: lessons from the nervous system. Science 262:695-700.
10. Holtzman, D. M., and M. Deshmukh. 1997. Caspases: a treatment target for neurodegenerative disease? Nat. Med. 3:954-955.
11. Kim, T. W., W. H. Pettingell, Y. K. Jung, et al. 1997. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. Science 277: 373-376.
12. Friedlander, R. M., R. H. Brown, V. Gagliardini, et al. 1997. Inhibition of ICE slows ALS in mice. Nature 388:31.
13. LeBlanc, A. 1998. Detection of actin cleavage in Alzheimer's disease. Am. J. Pathol. 152:329-332.
14. Banati, R. B., S. E. Daniel, and S. B. Blunt. 1998. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13:221-227.
15. Lassmann, H., C. Bancher, H. Breitschopf, et al. 1995. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol. (Berlin) 89:35-41.
16. Johnson, E. M. J., T. L. Deckwerth, and M. Deshmukh. 1996. Neuronal death in developmental models: possible implications in neuropathology. Brain Pathol. 6:397-409.
17. Choi, D. W. 1997. At the scene of ischemic brain injury: is PARP a perp? Nat. Med. 3:1073-1074.
18. Powers, J. M., and D. S. Horoupian. 1996. Central nervous system, p. 2693-2798. In I. Damjanov and J. Linder (ed.), Anderson's pathology. C. V. Mosby Co., St. Louis.
19. Ma, S. Y., J. O. Rinne, Y. Collan, et al. 1996. A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J. Neurol. Sci. 140:40-45.
20. Swaab, D. F., M. A. Hofman, P. J. Lucassen, et al. 1994. Neuronal atrophy, not cell death, is the main hallmark of Alzheimer's disease. Neurobiol. Aging 15:369-371.
21. Kumer, S. C., and K. E. Vrana. 1996. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67:443-462.
22. Nagai, T., P. L. McGeer, J. H. Peng, et al. 1983. Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls. Neurosci. Lett. 36:195-199.
23. Lassmann, H. 1996. Patterns of synaptic and nerve cell pathology in Alzheimer's disease. Behav. Brain Res. 78:9-14.
24. Hampel, H., S. J. Teipel, G. E. Alexander, et al. 1998. Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer's disease: a magnetic resonance imaging analysis. Arch. Neurol. 55:193-198.
25. Cullen, K. M., G. M. Halliday, K. L. Double, et al. 1997. Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience 78:641-652.
26. Regeur, L., G. B. Jensen, H. Pakkenberg, et al. 1994. No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol. Aging 15:347-352.
27. Haass, C., and D. J. Selkoe. 1993. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75:1039-1042.
28. Goate, A. M. 1998. Monogenetic determinants of Alzheimer's disease: APP mutations. Cell Mol. Life Sci. 54:897-901.
29. Games, D., D. Adams, R. Alessandrini, et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
30. Hsiao, K., P. Chapman, S. Nilsen, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
31. Johnson-Wood, K., M. Lee, R. Motter, et al. 1997. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94:1550-1555.
32. Sturchler-Pierrat, C., D. Abramowski, M. Duke, et al. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 94:13287-13292.
33. Hutton, M., and J. Hardy. 1997. The presenilins and Alzheimer's disease. Hum. Mol. Genet. 6:1639-1646.
34. De Strooper, B., P. Saftig, K. Craessaerts, et al. 1998. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390.
35. Citron, M., D. Westaway, W. Xia, et al. 1997. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 3:67-72.
36. Hornkiewica, O., and S. Kish. 1987. Biochemical pathophysiology of Parkinson's disease, p. 19-34. In M. Yahr and K. J. Bergmann (ed.), Parkinson's disease. Raven Press, New York.
37. Gibb, W. R. 1992. Neuropathology of Parkinson's disease and related syndromes. Neurol. Clin. 10:361-376.
38. Forno, L. S. 1996. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:259-272.
39. Fahn, S. 1988. Parkinsonism, p. 2143-2147. In J. B. Byngaarden and L. H. Smith, Jr. (ed.), Cecil's textbook of medicine. W. B. Saunders Co., Philadelphia.
40. Ungerstedt, U. 1968. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5:107-110.
41. Burns, R. S., C. C. Chiueh, S. P. Markey, et al. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80:4546-4550.
42. Polymeropoulos, M. H., C. Lavedan, E. Leroy, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
43. Kruger, R., W. Kuhn, T. Muller, et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:106-108.
44. Norremolle, A., O. Riess, J. T. Epplen, et al. 1993. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum. Mol. Genet. 2:1475-1476.
45. Walling, H. W., J. J. Baldassare, and T. C. Westfall. 1998. Molecular aspects of Huntington's disease. J. Neurosci. Res. 54:301-308.
46. Saudou, F., S. Finkbeiner, D. Devys, et al. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
47. Banfi, S., A. Servadio, M. Y. Chung, et al. 1994. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat. Genet. 7:513-520.
48. Mitsumoto, H. 1994. Classification and clinical features of amyotrophic lateral sclerosis. In H. Mitsumoto and H. Forbes (ed.), Amyotrophic lateral sclerosis. A comprehensive guide to management. Norris, New York.
49. Rosen, D. R., T. Siddique, D. Patterson, et al. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59-62.
50. Brown, R. H. J. 1998. SOD1 aggregates in ALS: cause, correlate or consequence? Nat. Med. 4:1362-1364.
51. Lemke, G. 1993. The molecular genetics of myelination: an update. Glia 7:263-271.
52. Snipes, G. J., and U. Suter. 1995. Molecular basis of common hereditary motor and sensory neuropathies in humans and in mouse models. Brain Pathol. 5:233-247.
53. Bell, C., N. Haites, C. S. Constantinescu, et al. 1997. The peripheral neuropathies and their molecular genetics. Immunol. Res. 36:1-44.
54. Constantinescu, C. S., B. Hilliard, T. Fujioka, et al. 1998. Pathogenesis of neuroimmunologic diseases. Experimental models. Immunol. Res. 17:217-227.
55. Valentijn, L. J., and F. Baas. 1998. Genetic basis of peripheral neuropathies. Prog. Brain Res. 117:249-264.